Covalent polar lipid-peptide conjugates for use in salves

• US 5,543,389 A
• Filed: 10/26/1993
• Issued: 08/06/1996
• Est. Priority Date: 11/01/1990
• Status: Expired due to Term

• Current Assignee: State of Oregon
• Original Assignee: Oregon State University (Oregon University System)
• Inventors: Stowell, Michael H B, Yatvin, Milton B.
• Primary Examiner(s): Rollins, John W.
• Application Number:
  US08/142,771
• Time in Patent Office: 1,015 Days
• Field of Search: 536/29, 536/51, 514/28, 514/2, 514/863, 424/450, 538/300, 538/331, 538/329, 544/243, 544/153
• US Class Current: 514/19.3
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 47/543 Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• CPC Class Codes: A61K 47/544 Phospholipids
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6903 the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

This invention herein describes a method of facilitating the entry of drugs into cells at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative drugs, in particular in combination with a multiplicity of other emolients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of antiproliferative agents through the epidermis for treatment of skin diseases such as psoriasis.

Claims

1. A composition of matter comprising an antiproliferative drug, a polar lipid carrier, two linker functional groups and a spacer, wherein the spacer has a first end and a second end and wherein the polar lipid is attached to the first end of the spacer through a first linker functional group and the antiproliferative drug is attached to the second end of the spacer through a second linker functional group.

2. The composition of matter of claim 1 wherein the drug is methotrexate.

3. A composition of matter according to claim 1 wherein the spacer allows the antiproliferative drug to act without being released at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.

4. A composition of matter according to claim 3 that is methotrexateglycylglycylglycylgylcyl ceramide ester.

5. A composition comprising the composition of matter of claim 4 and a medicinal ointment or salve.

6. A composition of matter according to claim 3 that is methotrexateglycylglycylglycylgylcyl ceramide ester.

7. A composition comprising the composition of matter of claim 6 and a medicinal ointment or salve.

8. A composition of matter according to claim 3 that is methotrexatevalinylvalinyl sphingosine amide.

9. A composition comprising the composition of matter of claim 8 and a medicinal ointment or salve.

10. A composition of matter according to claim 1 wherein the spacer allows the facilitated hydrolytic release of the antiproliferative drug at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.

11. A composition of matter according to claim 1 wherein the spacer allows the facilitated enzymatic release of the antiproliferative drug at an intracellular site and wherein the first linker functional group attached to the first end of the spacer is strong and the second linker functional group attached to the second end of the spacer is weak.

12. A composition of matter according to claim 1 wherein the polar lipid is sphingosine, ceramide, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, cardiolipin or phosphatidic acid.

13. A composition of matter according to claim 1 wherein the spacer is a peptide of formula (amino acid)_n, wherein n is an integer between 2 and 25, and the peptide comprises a polymer of a particular amino acid.

14. A composition of matter according to claim 1 that is methotrexate-[tri-β

-hydroxypropionylester]-O^x -ceramide ester.

15. A composition comprising the composition of matter of claim 14 and a medicinal ointment or salve.

16. A composition of matter according to claim 1 that is methotrexateaminohexanoyl sphingosine amide.

17. A composition comprising the composition of matter of claim 16 and a medicinal ointment or salve.

18. A composition comprising the composition of matter of claim 1 and a medicinal ointment or salve.

29. A method of treating a pathological condition or disease state in in skin of an animal, wherein the pathological condition or disease state results from an abnormal proliferation of cells in the animal, comprising the step of administering to the animal the composition of matter of claim 1 in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.

30. The method of claim 29 wherein the animal is a human.

31. The method of claim 29 wherein the disease is psoriasis.

32. A method according to claim 29, wherein the antiproliferative drug-polar lipid conjugate is formulated as a medicinal ointment or salve.

19. A composition of matter comprising an antiproliferative drug having a first functional linker group, and a polar lipid carrier having a second functional linker group, wherein the drug is covalently linked to the polar lipid carrier by a chemical bond between the first and second functional linker groups.

20. A composition of matter according to claim 19 wherein the first functional linker group is a hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.

21. A composition of matter according to claim 19 wherein the second functional linker group is a hydroxyl group, a primary or secondary amino group, a phosphate group or substituted derivatives thereof or a carboxylic acid group.

22. A composition of matter according to claim 19 wherein the polar lipid is sphingosine, ceramide, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine, cardiolipin or phosphatidic acid.

23. The composition of matter of claim 19 wherein the drug is methotrexate.

24. A composition of matter according to claim 19 that is methotrexate-O^x -ceramide ester.

25. A composition comprising the composition of matter of claim 24 and a medicinal ointment or salve.

26. A composition of matter according to claim 19 that is N-methotrexate ceramide.

27. A composition comprising the composition of matter of claim 26 and a medicinal ointment or salve.

28. A composition comprising the composition of matter of claim 19 and a medicinal ointment or salve.

33. A method of treating a pathological condition or disease state in in skin of an animal, wherein the pathological condition or disease state results from an abnormal proliferation of cells in the animal, comprising the step of administering to the animal the composition of matter of claim 19 in an acceptable carrier or formulation and in an amount sufficient to alleviate the pathological condition or disease state in the animal.

34. The method of claim 33 wherein the animal is a human.

35. The method of claim 33 wherein the disease is psoriasis.

36. A method according to claim 33, wherein the antiproliferative drug-polar lipid conjugate is formulated as a medicinal ointment or salve.